Latest filing published 18 Sept 2026 for Roivant Sciences Ltd.. Read the official filing
Keith S. Manchester discloses dealings in 2 companies, chiefly Roivant Sciences Ltd. and Arbutus Biopharma Corp. In total, 20 filings cover trades dated from 15 September 2022 to 16 September 2026.
No open-market purchase appears, only 11 sales worth €58.6M. The totals exclude 6 filings filed without an amount. Other entries cover 5 share grants and 1 option exercise. 2026 to date brings no purchases and 7 sales.
The latest filing, published on 18 September 2026, reports a share grant in Roivant Sciences Ltd. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Same trade as the filing by Daniel Allen Gold, counted once · View ↗
20 of 19 declarations